Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Protective Role of Melatonin in Chemotherapy‐Induced Nephrotoxicity: A Review of Non-Clinical Studies Publisher Pubmed



Haghiaminjan H1 ; Farhood B2 ; Rahimifard M3 ; Didari T3 ; Baeeri M3 ; Hassani S3 ; Hosseini R1 ; Abdollahi M1, 3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Departmentof Medical Physics and Radiology, Faculty of Paramedical Sciences, Kashan University of Medical Sciences, Kashan, Iran
  3. 3. Toxicology and Diseases Group, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran

Source: Expert Opinion on Drug Metabolism and Toxicology Published:2018


Abstract

BSTRACT: Introduction: The aim of this study was to investigate the potential role of melatonin in the prevention of chemotherapy-induced nephrotoxicity at the preclinical level. Areas to be covered: To illuminate the possible role of melatonin in preventing chemotherapy-related nephrotoxicity, Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline was followed. A comprehensive search strategy was developed to include PubMed, Web of Science, Scopus, and Embase electronic databases from their inception to May 2018. Based on a set of prespecified inclusion and exclusion criteria, 21 non-clinical articles were ultimately included in the study. Expert opinion: Our findings clearly demonstrate that melatonin has a protective role in the prevention of chemotherapy-induced nephrotoxicity which may be caused by different chemotherapy agents such as cyclophosphamide, cisplatin, doxorubicin, methotrexate, oxaliplatin, etoposide, and daunorubicin. On the basis of current review of non-clinical studies, this protective effect of melatonin is attributed to different mechanisms such as reduction of oxidative stress, apoptosis, and inflammation. The findings presented in this review are based on non-clinical studies and thus conducting appropriate clinical trials to evaluate the real effectiveness of the concurrent use of chemotherapy agents with melatonin in the cancer patients is necessary. © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.
Other Related Docs
16. Radiation-Induced Inflammation and Autoimmune Diseases, Military Medical Research (2018)
27. Evidence for the Benefits of Melatonin in Cardiovascular Disease, Frontiers in Cardiovascular Medicine (2022)
29. The Inhibitory Effect of Melatonin on the Proliferation of Irradiated A549 Cell Line, Journal of Cancer Research and Therapeutics (2020)